Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.09 USD | +2.37% | -4.05% | -33.24% |
Financials (USD)
Sales 2024 * | 1.54M | Sales 2025 * | 5.81M | Capitalization | 729M |
---|---|---|---|---|---|
Net income 2024 * | -201M | Net income 2025 * | -241M | EV / Sales 2024 * | 238 x |
Net cash position 2024 * | 362M | Net cash position 2025 * | 377M | EV / Sales 2025 * | 60.6 x |
P/E ratio 2024 * |
-3.67
x | P/E ratio 2025 * |
-3.35
x | Employees | 158 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.42% |
Latest transcript on Pliant Therapeutics, Inc.
1 day | +2.37% | ||
1 week | -4.05% | ||
Current month | -18.86% | ||
1 month | -18.86% | ||
3 months | -35.28% | ||
6 months | -9.78% | ||
Current year | -33.24% |
Managers | Title | Age | Since |
---|---|---|---|
Bernard Coulie
CEO | Chief Executive Officer | 58 | 16-01-31 |
- | - | ||
Keith Cummings
DFI | Director of Finance/CFO | 47 | 18-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 21-01-11 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 16-06-30 |
Gayle Crowell
BRD | Director/Board Member | 73 | 20-01-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.16% | 2 M€ | -.--% | ||
0.08% | 0 M€ | 0.00% | - | |
0.07% | 237 M€ | +3.51% | - | |
0.07% | 0 M€ | 0.00% | - | |
0.05% | 7 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 12.09 | +2.37% | 262,795 |
24-04-26 | 11.81 | -0.59% | 366,715 |
24-04-25 | 11.88 | -0.17% | 610,667 |
24-04-24 | 11.9 | -4.95% | 368,691 |
24-04-23 | 12.52 | -0.63% | 243,871 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.24% | 729M | |
+26.47% | 664B | |
+24.91% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.42% | 234B | |
+4.61% | 199B | |
-9.86% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- PLRX Stock